CryoCath CE-marks AF (Atrial Fibrillation)Arctic Front System
This article was originally published in Clinica
CryoCath Technologies has CE-marked for sale in Europe its Arctic Front catheter designed for the treatment of atrial fibrillation (AF), a condition characterised by rapid quivering of the two top chambers (atrium) in the heart. The company has also CE-marked its next-generation console for use with Arctic Front and its FlexCath deflectable sheath.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.